Quotient (QTNT) – Analysts’ Weekly Ratings Updates

Share on StockTwits

Several brokerages have updated their recommendations and price targets on shares of Quotient (NASDAQ: QTNT) in the last few weeks:

  • 5/23/2019 – Quotient was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 5/14/2019 – Quotient was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 5/8/2019 – Quotient was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
  • 5/7/2019 – Quotient was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 4/30/2019 – Quotient was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
  • 4/19/2019 – Quotient was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 4/10/2019 – Quotient was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
  • 4/5/2019 – Quotient was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 4/4/2019 – Quotient was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “

Shares of NASDAQ QTNT traded down $0.52 during mid-day trading on Thursday, reaching $8.97. The company had a trading volume of 243,064 shares, compared to its average volume of 351,635. The company has a current ratio of 6.87, a quick ratio of 6.05 and a debt-to-equity ratio of 4.95. The stock has a market cap of $623.00 million, a PE ratio of -4.44 and a beta of 1.25. Quotient Ltd has a 52 week low of $5.52 and a 52 week high of $11.15.

In other news, President Edward Farrell sold 22,500 shares of the company’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $8.67, for a total value of $195,075.00. Following the transaction, the president now directly owns 2,133 shares in the company, valued at $18,493.11. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 17.40% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC grew its holdings in Quotient by 22.8% during the 4th quarter. Perceptive Advisors LLC now owns 10,789,054 shares of the company’s stock worth $66,029,000 after acquiring an additional 2,000,000 shares in the last quarter. Polar Capital LLP grew its holdings in Quotient by 8.6% during the 4th quarter. Polar Capital LLP now owns 5,796,063 shares of the company’s stock worth $35,472,000 after acquiring an additional 458,908 shares in the last quarter. Highbridge Capital Management LLC grew its holdings in Quotient by 47.5% during the 4th quarter. Highbridge Capital Management LLC now owns 3,003,433 shares of the company’s stock worth $18,382,000 after acquiring an additional 967,096 shares in the last quarter. Morgan Stanley grew its holdings in Quotient by 151.1% during the 1st quarter. Morgan Stanley now owns 1,772,678 shares of the company’s stock worth $15,972,000 after acquiring an additional 1,066,682 shares in the last quarter. Finally, Broadfin Capital LLC grew its holdings in Quotient by 111.0% during the 4th quarter. Broadfin Capital LLC now owns 1,697,582 shares of the company’s stock worth $10,389,000 after acquiring an additional 892,882 shares in the last quarter. Institutional investors own 69.07% of the company’s stock.

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Read More: What is insider trading?

Receive News & Ratings for Quotient Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Ltd and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Expect Bank of Hawaii Co.  to Announce $1.38 Earnings Per Share
Analysts Expect Bank of Hawaii Co. to Announce $1.38 Earnings Per Share
Soarcoin 1-Day Trading Volume Tops $220.00
Soarcoin 1-Day Trading Volume Tops $220.00
Mason Graphite  Shares Up 5.6%
Mason Graphite Shares Up 5.6%
Continental Gold  Shares Up 0.7%
Continental Gold Shares Up 0.7%
Arcus Biosciences Inc  Short Interest Update
Arcus Biosciences Inc Short Interest Update
Hancock Whitney Corp  Given Average Rating of “Buy” by Analysts
Hancock Whitney Corp Given Average Rating of “Buy” by Analysts


 
© 2006-2019 Zolmax.